CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core Research Group: 2016 Updated Canadian HIV/Hepatitis C Adult Guidelines for Management and Treatment
Table 5
Summary of antiretroviral regimen recommendations for patients who require concomitant HIV and hepatitis C treatment.
Recommended
Alternative
Not recommended
Sofosbuvir 400 mg/ledipasvir 90 mg once daily
No restrictions with first or second line ART regimens
In patients with preexisting renal dysfunction or significant risk factors for nephrotoxicity: may wish to avoid tenofovir-containing regimens due to potential for ↑ tenofovir concentrations
Paritaprevir 150 mg/ritonavir 100 mg/ombitasvir 25 mg once daily + dasabuvir 250 mg BID with food
Atazanavir (without additional ritonavir), raltegravir, and Dolutegravir
Darunavir (without additional ritonavir)
Ritonavir- or cobicistat-boosted regimens; efavirenz, etravirine, and rilpivirine
Simeprevir 150 mg daily plus sofosbuvir 400 mg daily with food
Dolutegravir, raltegravir, or rilpivirine-based regimens
Ritonavir- or cobicistat-boosted regimens; efavirenz, etravirine, and nevirapine
Daclatasvir 60 mg daily plus sofosbuvir 400 mg daily
Atazanavir (requires decrease in daclatasvir dose to 30 mg daily), darunavir, dolutegravir, raltegravir, or rilpivirine-based regimens
Efavirenz (requires increase in daclatasvir dose to 90 mg daily)
